Printer Friendly

Genetic testing.

The subject of "Federal Neglect: Regulation of Genetic Testing," by Gail H. Javitt and Kathy Hudson (Issues, Spring 2006) is clearly an important one as advances in genetics and genomics contribute to the development of new genetic tests and services, driven by physician and patient demand for these diagnostic services. The number of genetic tests available is rising as the technology develops, as is the significant contribution that these tests make to individualized personal health care. Genetic tests can detect disease early, before the onset of symptoms, when treatment can be more effective; and can specifically target therapy for existing disease that is more effective for the individual patient. It must be the shared objective of all of us to ensure that patients obtain the full benefit of this revolutionary technology, to continue to encourage innovation, and to regulate in ways that are appropriate and do not create barriers to either patient access or innovation.

I must take exception to the article's alarmist premise that federal "neglect" in the oversight of genetic tests "represents a real threat to public health." In fact, the regulatory gap referred to by the author is illusory. The clinical laboratory industry is one of the most highly regulated health care-delivery sectors. All clinical lab services are regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). CLIA regulations are documented by hundreds of pages of specific and general requirements for laboratory quality, such as obligations to have appropriately trained personnel, establish quality-control programs, and engage in proficiency testing, which all apply to laboratories performing genetic testing. More important, CLIA regulations require that before a laboratory introduces a new method or test that does not use a commercially available test kit, it must establish and document the performance specifications for accuracy, precision, analytical sensitivity, analytical specificity, and quality of results for patient care: all essential parameters of quality and performance. These requirements are enforced by onsite inspections every two years. The penalties for noncompliance are severe and can lead to the revocation of the lab's CLIA certificate, without which a lab is unable to provide services.

The record indicates that laboratory tests are accurate and reliable and provide information relevant to the patient and his or her doctor. It is important that any proposed regulatory changes focus on risks specifically related to genetic tests and those that are targeted, realistic, and effective to meet any legitimate issues or risks. It is incumbent on all of us to work together to identify specific concerns and regulatory responses that will address those concerns without creating undue burdens that will stifle innovation or restrict patient access to new technology.

DAVID A. MONGILLO

Vice President for Policy and Medical Affairs

American Clinical Laboratory Association

Washington, DC

dmongillo@clinical-labs.org
COPYRIGHT 2006 National Academy of Sciences
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:FORUM
Author:Mongillo, David A.
Publication:Issues in Science and Technology
Geographic Code:1USA
Date:Jun 22, 2006
Words:459
Previous Article:Aquaculture and the environment.
Next Article:Taxes and highways.
Topics:


Related Articles
From Laboratories to Legislatures...
At-home genetic tests pose ethical dilemmas.
Passion drives Kimball Genetics.
Federal neglect: regulation of genetic testing; Government needs to ensure that genetic tests provide useful medical information and that the test...
Genetic testing: current and future trends.
Plunging into the gene pool: even though the legal landscape has changed, concerns about the abuse of genetic testing persist.
Gene pool: as new genetic tests make their way to market, some managed-care plans are adding them to their lists of covered benefits.
Era of genetic anti-discrimination law set to begin: the law, known as GINA, prohibits employers and health insurers from discriminating against...
Issues in genetic testing.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters